IOL Chemicals and Pharmaceuticals experienced a significant surge of 7.9% today, reaching Rs 130.9. The cause for this increase is currently unknown, according to MarketMojo's analysis.

IOL Chemicals aims to achieve mid to high-teen revenue growth by investing ₹1,200-1,400 crore in a multi-year expansion plan for their pharmaceutical division. The phased expansion over 4-5 years will fuel their strategic growth objectives within the sector.

IOL Chemicals reports a significant 71% year-on-year increase in Q4 profit, with earnings reaching ₹53 crore, while revenue also climbed by 17%, reaching ₹619 crore compared to the previous year.

IOLCP's financial year 2026 revenue showed a significant increase of 11.5%, reaching INR 2,319.1 crore. This growth was further reflected in the earnings, with EBITDA and PAT jumping by 29.3% and 36.4% respectively, to INR 290.4 crore and INR 137.7 crore respectively.

IOL Chemicals incurred a fine of INR 2,000 for a minor oversight in their BSE filing regarding the shareholding pattern, which was submitted one day late. Despite this, they successfully adhered to NSE's timeline, and the delay on BSE was due to an initial misunderstanding of rules.

IOL Chemicals achieves all-time high profits and revenues in March 2026, signaling a strong financial turnaround. Mojo has updated its recommendation for IOL Chemicals from Sell to Hold, indicating increased investor confidence despite sector difficulties.

IOL Chemicals & Pharmaceuticals has received an unmodified opinion from auditors for their financial results in the fiscal year 2026. The board has approved the establishment of a new Triacetin plant with a capacity of 6,000 MTPA and an expansion of Pantoprazole production capacity from 240 to 276 MTPA, both funded internally without external financing.

IOL Chemicals has reported a significant 47% increase in Q4 EBITDA, reaching INR 925 million compared to last year. The improved earnings margin rose to 14.9%, demonstrating stronger profitability for the company.

IOL Chemicals & Pharm experienced a 6% rise in its share price to reach Rs 103.3, marking a significant 62% year-on-year growth. Despite a 24.8% decrease in net profit for the fiscal year 2025, the BSE Healthcare Index increased slightly by 0.2%.

IOL Chemicals has revealed updated disclosures in accordance with Section 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. This move ensures transparency as per securities market regulations.

IOL Chemicals, known for its leadership in Ibuprofen, is expanding its product range by venturing into non-Ibuprofen APIs and increasing Paracetamol production. Despite a 10.9% revenue increase in Q3 FY26, the profit after tax (PAT) remained unchanged due to cost pressures and exceptional items. The company's growth is attributed to strong exports and new API developments.

IOL Chemicals, due to its recent price surge, is now deemed as having a high valuation relative to the industry standard, potentially making it less attractive compared to competitors in the sector. This shift in evaluation suggests a need for investors to reconsider their investment strategy regarding this company.